Advertisement

Topics

Expansion Therapeutics, Inc. Company Profile

18:48 EDT 18th August 2018 | BioPortfolio

Expansion Therapeutics is a drug discovery and development company pursuing the vast potential of small molecule medicines for RNA-mediated diseases. Based on exclusive worldwide rights to groundbreaking research from the laboratory of Matthew D. Disney, Ph.D., at The Scripps Research Institute, Expansion has assembled the intellectual property, know-how, and proprietary enabling technologies and tools necessary to facilitate the creation of potent and specific small molecule binders of RNA. Through this unique platform, Expansion is building a portfolio of novel RNA-targeted drug candidates with activity across a broad number of disease indications. The company’s initial development focus is on therapies for patients with expansion repeat diseases who currently have limited and unsatisfactory treatment options. Expansion is based in San Diego, California and Jupiter, Florida.


News Articles [816 Associated News Articles listed on BioPortfolio]

Evox Therapeutics expands into new facilities at Oxford Science Park

The exosome therapeutics company announced the expansion will enhance its research and development capabilities and will facilitate its growth

Nimbus Therapeutics raises $65m in new capital to expand discovery efforts

Nimbus Therapeutics has raised $65m in new capital to accelerate its pipeline progress and fuel its expansion into new high-value targets aimed at overlapping biological mechanisms in immunology, onco...

Checkpoint Therapeutics aiming to be phase 3 ready by Q1 of 2019.

CEO James Oliviero tells Proactive Investors that Checkpoint Therapeutics (NASDAQ:CKPT) is aiming to finish dose escalation next month to bring in dose expansion patients to head for phase 3 early n...

Nimbus Therapeutics secures $65m to accelerate pipeline progress and expand discovery effort

Nimbus Therapeutics has raised $65m in new capital to accelerate its pipeline progress and fuel its expansion into new high-value targets aimed at overlapping biological mechanisms in immunology, onco...

Aileron Therapeutics Announces Expansion of Scientific Advisory Board

CAMBRIDGE, Mass., March 28, 2018 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ:ALRN), the clinical-stage leader in the field of stapled peptide therapeutics for cancers and other diseases, tod...

Checkpoint Therapeutics Initiates Dose Expansion Portion of Phase 1 Trial of Anti-PD-L1 Antibody CK-301

NEW YORK, March 21, 2018 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ:CKPT), a clinical-stage, immuno-oncology biopharmaceutical company focused on the acquisition...

Proteostasis Therapeutics Announces Withdrawal of Equity Offering Due to Market Conditions

About Proteostasis Therapeutics, Inc. Proteostasis Therapeutics, Inc. is a clinical stage biopharmaceutical company developing small molecule therapeutics to treat cystic fibrosis (CF) and other di...

Technical Perspectives on Biotech Stocks -- Adaptimmune Therapeutics, Akebia Therapeutics, ...

www.wallstequities.com/registration Adaptimmune Therapeutics Shares in Abingdon, the UK headquartered Adaptimmune Therapeutics PLC rose slightly by 0.41%, ending Wednesday's trading session at $12...

PubMed Articles [884 Associated PubMed Articles listed on BioPortfolio]

The PICKING technique for self-expanding nitinol stent expansion of an extremely calcified lesion in the femoropopliteal artery: the tail makes the difference.

Utilizing T-cell Activation Signals 1, 2, and 3 for Tumor-infiltrating Lymphocytes (TIL) Expansion: The Advantage Over the Sole Use of Interleukin-2 in Cutaneous and Uveal Melanoma.

In this study, we address one of the major critiques for tumor-infiltrating lymphocyte (TIL) therapy-the time needed for proper expansion of a suitable product. We postulated that T-cell receptor acti...

The effect on the immunology laboratory of the expansion in complement therapeutics.

The approval in the US and Europe of Eculizumab in 2007 marked a change in complement therapeutics, and with it the landscape for complement testing in the clinical immunology laboratory changed. The ...

RNA Therapeutics (Almost) Comes of Age: Targeting, Delivery and Endosomal Escape.

Prevalence of immunological diseases in a Finnish frontotemporal lobar degeneration cohort with the C9orf72 repeat expansion carriers and non-carriers.

Recent studies have suggested a role for immune dysregulation behind the etiology of frontotemporal lobar degeneration (FTLD). Here, we have investigated the prevalence of immunological diseases in FT...

Clinical Trials [754 Associated Clinical Trials listed on BioPortfolio]

Impact of Ibis on Patients With Advanced COPD

The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients wi...

HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia

Assess the effect on coronary atheroma of serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System

Study of Tissue Expansion Devices Complications

Reduce the common complications incidence about patients placed tissue expansion devices to around 5%.

Sharp Versus Blunt Uterine Incision Expansion

comparison between blunt versus sharp expansion of uterine incision at lower segment cesarean section in primigravida as regards the intra-operative blood loss & postoperative pain

Ontogenesis of the P-Glycoprotein in Human Lymphocytes Influence of HIV and Antiretroviral Therapeutics

The P-glycoprotein (P-gp) is a membranous transporter that modulates the intracellular concentrations of many drugs and plays thus a major role in the efficacy of the therapeutics that act...

Companies [1461 Associated Companies listed on BioPortfolio]

Expansion Therapeutics, Inc.

Expansion Therapeutics is a drug discovery and development company pursuing the vast potential of small molecule medicines for RNA-mediated diseases. Based on exclusive worldwide ...

Parvus Therapeutics

Parvus Therapeutics Inc. is a privately held biopharmaceutical company engaged in the development and commercialization of Navacim therapeutics, novel nanoparticle based immune co...

Parvus Therapeutics Inc.

Parvus Therapeutics Inc. is a privately-held biopharmaceutical company engaged in the development and commercialization of Navacim therapeutics, novel nanoparticle based immune co...

Phoenix Children’s Hospital

Phoenix Children’s Hospital, ranked in U.S. News & World Report’s Best Children’s Hospitals, is Arizona’s only licensed children’s hospital, providing wor...

VGTI Florida

VGTI Florida is the Florida-funded expansion of Oregon Health & Science University's highly successful Vaccine and Gene Therapy Institute. Research at the facility will focus on v...

More Information about "Expansion Therapeutics, Inc." on BioPortfolio

We have published hundreds of Expansion Therapeutics, Inc. news stories on BioPortfolio along with dozens of Expansion Therapeutics, Inc. Clinical Trials and PubMed Articles about Expansion Therapeutics, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Expansion Therapeutics, Inc. Companies in our database. You can also find out about relevant Expansion Therapeutics, Inc. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...


Corporate Database Quicklinks



Searches Linking to this Company Record